1
EXHIBIT 99(a)(10)



INVERESK ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD REGARDING
PENDING ACQUISITION OF CLINTRIALS RESEARCH INC., SCOTLAND, MARCH 20, 2001 -
Inveresk Research Group Limited announced the expiration of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
applicable to Inveresk's pending acquisition of ClinTrials Research Inc.
(NASDAQ: CCRO). As previously announced, Inveresk Research Group Limited and
ClinTrials Research Inc. have entered into a merger agreement pursuant to which
an indirect wholly owned subsidiary of Inveresk, Indigo Acquisition Corp.,
commenced on March 5, 2001, a tender offer for all outstanding shares of common
stock of ClinTrials Research Inc. at an offer price of $6.00 per share, net to
the seller in cash. The offer is conditioned upon, among other things,
ClinTrials' shareholders tendering and not withdrawing prior to the expiration
of the offer at least a majority of the shares of ClinTrials' common stock,
calculated on a fully diluted basis. The tender offer and withdrawal rights are
scheduled to expire at 12:00 midnight, New York City time, on Monday, April 2,
2001, unless the offer is extended. The tender offer may be extended on the
terms and conditions stated in the Offer to Purchase, dated March 5, 2001, which
is available from the information agent for the offer: Morrow & Co., 445 Park
Avenue, 5th Floor, New York, New York 10022; (800) 654-2468 (bankers and
brokers); (800) 607-0088 (stockholders). Bear, Stearns & Co. Inc. ((888)
261-1668) is the dealer manager for the offer.

ClinTrials is a global contract research organization headquartered near
Research Triangle Park, North Carolina with offices in Maidenhead, England;
Glasgow, Scotland; Montreal, Canada; Brussels, Belgium; Paris, France;
Melbourne, Australia; Tel Aviv, Israel; Milan, Italy; Warsaw, Poland; Madrid,
Spain; and Munich, Germany. With more than 1,500 employees, ClinTrials provides
comprehensive research services, including monitoring, data management and
biostatistics, medical and regulatory services to pharmaceutical, biotechnology
and medical device clients.

Headquartered near Edinburgh, Scotland, Inveresk is a leading European provider
of contract research services, primarily to the pharmaceutical and biotechnology
industry.

THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS ABOUT
FUTURE BUSINESS OPERATIONS, FINANCIAL PERFORMANCE AND MARKET CONDITIONS. SUCH
FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES INHERENT IN BUSINESS
FORECASTS. THIS RELEASE IS NEITHER AN OFFER TO PURCHASE NOR A SOLICITATION OF AN
OFFER TO SELL SECURITIES OF CLINTRIALS RESEARCH INC. THE TENDER OFFER IS BEING
MADE SOLELY BY AN OFFER TO PURCHASE AND RELATED LETTER OF TRANSMITTAL
DISSEMINATED UPON THE COMMENCEMENT OF THE TENDER OFFER AND AMENDED FROM TIME TO
TIME. SHAREHOLDERS OF CLINTRIALS RESEARCH INC. SHOULD READ THE TENDER OFFER
STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION. THESE DOCUMENTS ARE
AVAILABLE TO CLINTRIALS SHAREHOLDERS AT NO CHARGE AND ARE ALSO AVAILABLE FOR
FREE AT THE SEC'S WEB SITE (HTTP://WWW.SEC.GOV).

CONTACT: GCI Christopher Gordon (212) 886-3428, ClinTrials Research, Inc. Paul
Ottaviano Chief Executive Officer (919) 460-9005